for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Unum Therapeutics Inc

UMRX.OQ

Latest Trade

1.01USD

Change

-0.05(-4.72%)

Volume

16,585

Today's Range

1.00

 - 

1.05

52 Week Range

1.00

 - 

8.25

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.06
Open
1.05
Volume
16,585
3M AVG Volume
0.98
Today's High
1.05
Today's Low
1.00
52 Week High
8.25
52 Week Low
1.00
Shares Out (MIL)
30.66
Market Cap (MIL)
33.73
Forward P/E
-0.85
Dividend (Yield %)
--

Latest Developments

More

Unum Therapeutics Reports Q3 Loss Per Share $0.39

Unum Therapeutics Announces Developing Cellular Therapies For Solid Tumor Cancers

Unum Therapeutics Says Q2 Loss Per Share $0.34

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Unum Therapeutics Inc

Unum Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the developing and commercializing of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. Its proprietary technology, called antibody-coupled T cell receptor (ACTR), is a universal, engineered cell therapy that is used in combination with a range of tumor-specific antibodies to target different tumor types. The Company's product candidates are composed of ACTR T cells co-administered with approved and commercially available antibodies or antibodies in preclinical or clinical development. The ACTR platform to transform cancer treatment and deliver patient cures in many different hematologic and solid tumor cancers, improving upon current cell therapies. The Company's product pipeline that includes clinical stage product candidates: ACTR087, ACTR087 (SEA-BCMA) and ACTR707.

Industry

Biotechnology & Drugs

Contact Info

200 Cambridgepark Dr Ste 3100

+1.617.9455576

https://www.unumrx.com/

Executive Leadership

Bruce Booth

Independent Chairman of the Board

Charles Wilson

President, Chief Executive Officer, Director

Matthew Scott Osborne

Chief Financial Officer

Geoffrey Hodge

Chief Technology Officer

John L. Green

Principal Accounting Officer, Controller, Senior Director of Finance

Key Stats

2.00 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-1.390

2019(E)

-1.295
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.80
Price To Book (MRQ)
0.85
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-66.68
Return on Equity (TTM)
-47.64

Latest News

Latest News

BRIEF-Unum Therapeutics Posts Q1 Loss Of $0.66 Per Share

* UNUM THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up